Company News Summary
Starpharma Holdings Receives $7.7m R&D Tax Incentive Refund
20 Jan 2022 | 08:55:00 | Associate analysts | Increase | Decrease | 
Original announcement: Starpharma receives $7.7M R&D tax incentive refund
Starpharma Holdings announced that it has received a $7.7m research and development (R&D) tax incentive refund related to the Company's Australian and international R&D expenses from the 2021 financial year. The tax refund is for eligible R&D activities across its portfolio, including the Company's DEP oncology products and VIRALEZE antiviral nasal spray.
See more ASX300 News Announcements